CardioComm Solutions Issue Stock Options
CardioComm Solutions Issue Stock Options
Toronto, Ontario--(Newsfile Corp. - July 28, 2022) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has issued 125,000 stock options to Etienne Grima, the Company's CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per Share for five years from the date of grant and vest immediately. The grant is subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
安大略省多倫多-(Newsfile Corp.-2022年7月28日)-美國心臟通訊解決方案公司(TSXV：EKG)(“心電聯動“或”公司)，一家全球消費者心臟監測和醫療心電圖儀的醫療供應商(心電信號“)軟件解決方案公司宣佈，它已根據公司首席執行官Etienne Grima的僱傭協議向他發行了125,000份股票期權。這些期權可在授予和立即授予之日起五年內以每股0.05美元的價格行使。授予受制於公司股票期權計劃、多倫多證券交易所創業板政策和適用的證券法的規定。
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at and .
欲瞭解更多有關HearoComm公司產品的信息，以及有關HeartCheck™心電設備集成的進一步更新，請訪問該公司的網站和。
About CardioComm Solutions
關於心通解決方案
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
心臟通訊解決方案公司的專利和專有技術用於記錄、觀看、分析和存儲心電，用於心臟病患者的診斷和管理。產品通過外部分銷網絡和北美銷售團隊銷往世界各地。心臟通信解決方案公司已獲得國際標準化組織13485認證，符合美國食品和藥物管理局的要求，並獲得歐盟(CE標誌)、美國食品和藥物管理局(FDA)和加拿大衞生部(Health Canada)的許可。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
欲瞭解更多信息，請聯繫：
首席執行官艾蒂安·格里馬
1-877-977-9425 x227
郵箱：egrima@core ocomsoltions.com
郵箱：Investor.Relationship@Hearocomsoltions.com
Forward-looking statements
前瞻性陳述
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
本新聞稿可能包含有關心臟通信解決方案公司的財務狀況、經營和業務結果以及心臟通信解決方案公司與這些項目有關的某些計劃和目標的前瞻性陳述和前瞻性信息。這些陳述和信息反映了管理層目前的信念，並以管理層目前掌握的信息為基礎。就其性質而言，前瞻性陳述和前瞻性信息涉及風險和不確定性，因為它們與事件有關，並取決於未來發生的情況，而且有許多因素可能導致實際結果和事態發展與這些前瞻性陳述和前瞻性信息明示或暗示的情況大不相同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在評估這些陳述時，讀者不應過分依賴前瞻性陳述和前瞻性信息。除適用法律要求外，公司不承擔更新本新聞稿中包含的前瞻性陳述和前瞻性信息的任何義務，包括但不限於國家文書51-102(持續披露義務).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。